DigitalOptic-NobleBio, MOU with US Livingston... "Start Selling COVID-19 Transport Kits in the US"

[Asia Economy Reporter Hyunseok Yoo] Digital Optic announced on the 24th that it has signed a strategic business agreement (MOU) with the Livingston Group in the United States, together with Noble Bio, for the sale of COVID-19 transport kits in the U.S. market.

Currently, the CTM (virus specimen collection and transport medium kit) supplied by Digital Optic domestically requires manufacturing facilities within the U.S. to enable local sales. Therefore, based on this MOU, Digital Optic plans to collaborate with the Livingston Group on expanding manufacturing facilities related to COVID-19 specimen transport kits, obtaining approvals, and other related efforts.

Through this, Digital Optic expects to supply FDA-approved COVID-19 specimen transport kits throughout the United States.

Founded in 1999, the Livingston Group has established a diverse network including 14 global affiliates, providing strategic business solutions to its clients. Robert L. Livingston, founding partner of the Livingston Group, is a two-term re-elected Louisiana Republican legislator and a former attorney. Other executives also come from backgrounds such as attorneys and legislative directors in the House of Representatives, possessing extensive networks in legal, congressional, and both public and private sectors.

Based on this, it is expected that Digital Optic will be able to collaborate with U.S. government officials and others for the entry of its COVID-19 transport kits into the U.S. market.

A company representative stated, “Noble Bio’s COVID-19 transport kit is a product that has received FDA emergency approval, and through this MOU, we plan to establish manufacturing facilities in the U.S. and begin full-scale supply,” adding, “Although the U.S. is accelerating vaccination efforts recently, even after vaccination, it is necessary to use neutralizing antibody diagnostic kits to confirm antibody production, so demand for specimen collection kits such as swabs and transport media will continue to increase.”

They continued, “Based on this MOU, by entering the U.S. market, which has been institutionally limited until now, Noble Bio will be able to further solidify the position of its domestically produced CTM (virus specimen collection and transport medium kit) products.”